66 related articles for article (PubMed ID: 1355363)
1. The amino-terminal peptide of HIV-1 glycoprotein 41 lyses human erythrocytes and CD4+ lymphocytes.
Mobley PW; Curtain CC; Kirkpatrick A; Rostamkhani M; Waring AJ; Gordon LM
Biochim Biophys Acta; 1992 Aug; 1139(4):251-6. PubMed ID: 1355363
[TBL] [Abstract][Full Text] [Related]
2. The amino-terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: peptide conformation, orientation and aggregation.
Gordon LM; Curtain CC; Zhong YC; Kirkpatrick A; Mobley PW; Waring AJ
Biochim Biophys Acta; 1992 Aug; 1139(4):257-74. PubMed ID: 1355364
[TBL] [Abstract][Full Text] [Related]
3. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41.
Gordon LM; Waring AJ; Curtain CC; Kirkpatrick A; Leung C; Faull K; Mobley PW
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):677-86. PubMed ID: 7576927
[TBL] [Abstract][Full Text] [Related]
4. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin.
Gordon LM; Curtain CC; McCloyn V; Kirkpatrick A; Mobley PW; Waring AJ
AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1145-56. PubMed ID: 8312056
[TBL] [Abstract][Full Text] [Related]
5. Membrane-perturbing domains of HIV type 1 glycoprotein 41.
Mobley PW; Pilpa R; Brown C; Waring AJ; Gordon LM
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):311-27. PubMed ID: 11242518
[TBL] [Abstract][Full Text] [Related]
6. Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs.
Mobley PW; Waring AJ; Sherman MA; Gordon LM
Biochim Biophys Acta; 1999 Apr; 1418(1):1-18. PubMed ID: 10209206
[TBL] [Abstract][Full Text] [Related]
7. Membrane perturbing actions of HIV type 1 glycoprotein 41 domains are inhibited by helical C-peptides.
Mobley PW; Barry JA; Waring AJ; Sherman MA; Gordon LM
AIDS Res Hum Retroviruses; 2007 Feb; 23(2):224-42. PubMed ID: 17331029
[TBL] [Abstract][Full Text] [Related]
8. The amino-terminal peptide of HIV-1 glycoprotein 41 fuses human erythrocytes.
Mobley PW; Lee HF; Curtain CC; Kirkpatrick A; Waring AJ; Gordon LM
Biochim Biophys Acta; 1995 Jun; 1271(2-3):304-14. PubMed ID: 7605797
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein.
Gordon LM; Nisthal A; Lee AB; Eskandari S; Ruchala P; Jung CL; Waring AJ; Mobley PW
Biochim Biophys Acta; 2008 Oct; 1778(10):2127-37. PubMed ID: 18515070
[TBL] [Abstract][Full Text] [Related]
10. Conformational partitioning of the fusion peptide of HIV-1 gp41 and its structural analogs in bilayer membranes.
Maddox MW; Longo ML
Biophys J; 2002 Dec; 83(6):3088-96. PubMed ID: 12496080
[TBL] [Abstract][Full Text] [Related]
11. The human erythrocyte anion-transport protein. Partial amino acid sequence, conformation and a possible molecular mechanism for anion exchange.
Brock CJ; Tanner MJ; Kempf C
Biochem J; 1983 Sep; 213(3):577-86. PubMed ID: 6615451
[TBL] [Abstract][Full Text] [Related]
12. Membrane-anchored peptide inhibits human immunodeficiency virus entry.
Hildinger M; Dittmar MT; Schult-Dietrich P; Fehse B; Schnierle BS; Thaler S; Stiegler G; Welker R; von Laer D
J Virol; 2001 Mar; 75(6):3038-42. PubMed ID: 11222732
[TBL] [Abstract][Full Text] [Related]
13. Simulation of the N-terminus of HIV-1 glycoprotein 41000 fusion peptide in micelles.
Langham A; Kaznessis Y
J Pept Sci; 2005 Apr; 11(4):215-24. PubMed ID: 15635657
[TBL] [Abstract][Full Text] [Related]
14. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
15. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion.
Suárez T; Gallaher WR; Agirre A; Goñi FM; Nieva JL
J Virol; 2000 Sep; 74(17):8038-47. PubMed ID: 10933713
[TBL] [Abstract][Full Text] [Related]
16. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor.
Cohen T; Pevsner-Fischer M; Cohen N; Cohen IR; Shai Y
Biochemistry; 2008 Apr; 47(16):4826-33. PubMed ID: 18376816
[TBL] [Abstract][Full Text] [Related]
18. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
Muñoz-Barroso I; Durell S; Sakaguchi K; Appella E; Blumenthal R
J Cell Biol; 1998 Jan; 140(2):315-23. PubMed ID: 9442107
[TBL] [Abstract][Full Text] [Related]
19. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
20. Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.
Harvima IT; Harvima RJ; Nilsson G; Ivanoff L; Schwartz LB
Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):711-8. PubMed ID: 8318003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
